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a b s t r a c t
Background: Catheter ablation has become an established therapy for the treatment of atrial ﬁbrillation
(AF). To obtain a perspective on the current status of this therapy in Japan, the Japanese Heart Rhythm
Society (JHRS) conducted a nationwide survey, the Japanese Catheter Ablation Registry of Atrial
Fibrillation (J-CARAF). In this study, we focused on whether periprocedural use of novel oral antic-
oagulants (NOACs) was related with excessive thromboembolic or bleeding complications.
Methods: Using an online questionnaire, JHRS requested electrophysiology centers in Japan to register
the data of patients who underwent AF ablations in September 2011, March 2012, and September 2012.
We compared the clinical proﬁles and ablation data, including the incidence of complications among
patients in whom warfarin, a NOAC or neither was used as a periprocedural anticoagulant.
Results: A total of 179 centers submitted data relating to 3373 patients (62.2710.6 years). Paroxysmal
atrial ﬁbrillation (PAF) was observed in 64.4% of patients. Warfarin, as a periprocedural oral antic-
oagulant, was used by 53.6% (1808/3373) of patients. A NOAC was given to 541 subjects (dabigatran: 504
[16.1%], rivaroxaban: 37 [1.1%]). In the remaining 1024 patients (30.4%), no periprocedural oral antic-
oagulants (OACs) were used. The proportion of PAF in warfarin-treated patients (61.1%) was signiﬁcantly
lower than that in NOAC-treated patients (70.1%, po0.01) or in patients not treated with an OAC (67.4%,
po0.01). Patients treated with uninterrupted warfarin therapy were associated with signiﬁcantly higher
CHA2DS2-VASc scores. A total of 158 complications occurred in 151 subjects (4.5%). The incidence of
complications in NOAC-treated patients (14/541 [2.6%]) was lower than that in patients receiving
uninterrupted warfarin therapy (4.8%, po0.05). The incidence of pericardial effusion in NOAC-treated
patients (0.7%) was lower than in warfarin-treated patients (2.6%, po0.05). The difference in the
periprocedural anticoagulant strategy was not related to the frequency of other bleeding events. Cerebral
infarction occurred in one patient from each patient group.
Conclusions: Our results suggest that NOACs are safe for use as substitutes for warfarin without causing
excessive increases in the rates of thromboembolic or bleeding complications.
& 2014 Japanese Heart Rhythm Society. Published by Elsevier B.V. All rights reserved.
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1. Introduction
Catheter ablation has become a potent and feasible therapy for
atrial ﬁbrillation (AF). Many clinical studies [1–3] have conﬁrmed
the safety, mid-term and long-term effectiveness, and cost-
effectiveness of this procedure. However, as technological and
technical innovations are continuously being introduced into
practice, constant effort is necessary to conﬁrm whether catheter
ablation, now carried out worldwide, is performed in accordance
with international standards [4]. The Japanese Heart Rhythm
Society (JHRS) conducted a nationwide registry of patients who
underwent catheter ablation for AF: the Japanese Catheter Abla-
tion Registry of Atrial Fibrillation (J-CARAF) [5,6].
Many studies have supported the view that uninterrupted
warfarin therapy is superior to interrupted anticoagulation ther-
apy with respect to intra- and post-procedural thromboembolic
and bleeding events [7–10]. Additionally, several recent studies
have suggested that novel oral anticoagulants (NOACs) could be
used a substitute for warfarin to maintain anticoagulant manage-
ment during AF ablation [11–15]. In this study, we focused on the
use of NOACs and warfarin. The aim of this analysis was to assess
the safety and feasibility of the use of NOACs as a periprocedural
anticoagulant.
2. Methods
The method of this survey has been reported previously [5]. In
short, the survey was performed retrospectively using an online
questionnaire. JHRS members were notiﬁed by e-mail, and data
relating to patient background, methods of pulmonary vein isola-
tion and related techniques, complications, and pre- and post-
procedural pharmacological treatments were collected for AF
ablation sessions performed in September 2011, May 2012, and
September 2012. Patient data included age, gender, previous AF
ablation, AF type (paroxysmal [PAF], persistent, or long-standing
[LS] persistent), thromboembolism risk factors, and echocardio-
graphic parameters. When warfarin or a NOAC was intentionally
continued on the day of, or until the day before, the index AF
ablation was performed, warfarin or a NOAC was considered to
have been used periprocedurally.
We preliminarily compared clinical outcomes between patients
treated with dabigatran or rivaroxaban and found no apparent
differences in the incidence or type of complications. Because the
number of subjects treated with rivaroxaban included in this study
was small, we collectively analyzed the data from patients treated
with any NOAC.
The continuous variables with a normal distribution were
expressed as mean7SD. Comparison of the continuous variables
among three study groups was performed by one-way analysis of
variance with a post hoc Bonferroni test. Categorical variables were




In total, 235 institutes responded to the survey, and 179 of these
reported data from 3373 AF ablation sessions. The average patient age
was 62.2710.6 years, and 76.1% (2587) were male. Of all sessions,
77.4% were ﬁrst AF ablation sessions. Patients with PAF constituted
64.4% (n¼2173), while persistent and LS-persistent AF constituted
21.7% and 13.8% (n¼733 and 467) of all patients, respectively.
3.2. Periprocedural anticoagulant strategies
As a periprocedural OAC, warfarin was given to 53.6% of
patients (1808/3373). Dabigatran and rivaroxaban were used in
504 (14.9%) and 37 subjects (1.1%), respectively. In total, 541
patients (16.0%) took a NOAC until the day before AF ablation or
until a time that physicians considered appropriate. In the remain-
ing 1024 patients (30.4%), an OAC was fully discontinued before AF
ablation or was not given at all.
3.3. Comparison of patient proﬁles
As shown in Table 1, the proportion of PAF in those treated
with warfarin (61.1%) was signiﬁcantly smaller than in those
treated with NOAC (70.1%, po0.01) or in those receiving no OAC
treatment (67.4%, po0.01). Lone AF was less frequent in patients
receiving uninterrupted warfarin treatment (20.2%) than in those
taking a NOAC (25.3%) or no OAC (26.1%). The CHA2DS2-VASc
score was signiﬁcantly greater in warfarin-treated patients
(po0.0001) than in patients treated with a NOAC or no OAC.
3.4. Outcome events
A total of 158 complications occurred in 151 subjects (4.5%).
The number of each type of event is shown in Table 2. As shown in
Fig. 1, the incidence of complications in NOAC-treated patients
(2.6%, 14/541) was lower than that in the uninterrupted warfarin
group (4.8%, po0.05). Pericardial effusion occurred in 75 of 151
subjects (2.2% of 3373). Incidence of pericardial effusion in NOAC-
treated patients (0.7%, Fig. 1) was lower than that in warfarin-
treated patients (2.6%, po0.05). Other bleeding events, namely
hemothorax, hematoma at the puncture site, and retroperitoneal
hematoma, were seen in 12 (1.2% of 1024), 15 (0.8% of 1808), and 3
(0.6% of 541) patients from each study group, respectively. There
was no signiﬁcant difference in the incidence of bleeding events.
Table 1
Comparison of clinical proﬁles and ablation data among the patients the three study groups.
No. No OAC Warfarin NOAC p Value
1024 1808 541 No OAC vs. warfarin Warfarin vs. NOAC No OAC vs. NOAC
Age/year 61.6711.0 63.0710.2 60.4710.8 o0.001 o0.0001
PAF 690 (67.4%) 1104 (61.1%) 379 (70.1%) o0.01 o0.01
Lone AF 267 (26.1%) 366 (20.2%) 137 (25.3%) o0.01 o0.05
CHA2DS2-VASc score 1.6371.41 1.8771.47 1.5171.32 o0.0001 o0.0001
LVEF/% 64.579.7 62.9710.2 65.078.8 o0.0001 o0.0001
LAD/mm 40.677.6 40.676.5 39.776.3 o0.01 o0.05
1st ablation 771 (75.3%) 1386 (76.7%) 453 (83.7%) o0.01 o0.01
Procedure time/h 3.6871.43 3.4971.20 3.2771.24 o0.001 o0.001 o0.0001
OAC: oral anticoagulant, NOAC: novel oral anticoagulant, LVEF: left ventricular ejection fraction, and LAD: left atrial diameter
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Cerebral infarction occurred in only one patient from each
study group. One patient in the no OAC group presented TIA. Thus,




The major ﬁndings of the present study are: (1) approximately
70% of AF ablation sessions were performed with periprocedural
OAC treatment, (2) an NOAC was used in 25% of patients who had
undergone AF ablation with periprocedural OAC treatment, (3) the
uninterrupted warfarin group was characterized by a lower
proportion of PAF, lone AF, and longer procedure times, and (4)
the incidence of acute complications in NOAC-treated patients was
lower than that in the uninterrupted warfarin patients.
4.2. Earlier studies
In an earlier non-randomized study [16], the perioperative use
of dabigatran was related with a higher risk of bleeding or
thromboembolic events than the uninterrupted use of warfarin.
This study suggested that the timing of discontinuation or re-
administration of dabigatran and interaction with heparin might
be related with excessive or insufﬁcient anticoagulant effects. In
another randomized study by Kim et al. [12], dabigatran discon-
tinued for 24 h before AF ablation was as safe and effective in
avoiding adverse events during and after AF ablation as unin-
terrupted warfarin treatment. A recent meta-analysis [11] that
analyzed 3841 cases from 11 studies revealed that cardiac tampo-
nade in 1.4% of patients treated with dabigatran and in 1.1% of
patients treated with warfarin (p¼not signiﬁcant). Thromboem-
bolic events occurred in 0.6% of dabigatran-treated patients and
0.1% of warfarin-treated patients (p¼0.12).
4.3. Interpretation of the present results
In the present study, thromboembolic or hemorrhagic events
did not show any apparent increase in NOAC-treated patients.
Overall complications and pericardial effusion were signiﬁcantly
less frequent in NOAC-treated patients than uninterrupted
warfarin-treated patients. Although not statistically signiﬁcant,
hematoma at the site of puncture was relatively less frequent in
patients treated with a NOAC. Each NOAC has a shorter half-life
than warfarin. Therefore, the anticoagulant action of the NOACs
may have all but disappeared during the procedure. The few
pericardial effusion and bleeding complications may be attribu-
table in part to this assumption.
Furthermore, differences in clinical proﬁles between patient
groups may explain the apparent disparity of complications
between the groups. Higher CHA2DS2-VASc scores, a smaller
proportion of lone AF and PAF, and prolonged procedure times
might indicate that warfarin was used preferentially in patients
with more complex and complicated proﬁles. Taking the diverse
Table 2
Number of complications in three patient groups.
No. of patients No OAC Warfarin NOAC Total
102 1808 541 3373
PE (no drainage) 11 18 3 32
PE (drainage) 13 29 1n 43
Transient AVB 0 3 1 4
AVBþtemporary pacing 0 0 0 0
AVBþpermanent pacemaker 0 0 0 0
Sinus arrest 5 5 1 11
TIA 1 0 0 1
Cerebral infarction 1 1 1 3
Asymptomatic cerebral infarction (MRI) 1 4 1 6
Pneumothorax 0 1 0 1
Hemothorax 0 1 0 1
Prolonged phrenic nerve paresthesia 1 3 1 5
Air embolism 2 3 0 5
Pulmonary vein stenosis 0 0 0 0
Arteriovenous ﬁstula 1 0 2 3
Hematoma at the puncture site 12 14 3 29
Retroperitoneal hematoma 0 0 0 0
Pseudoaneurysm 1 3 0 4
Atrioesophageal ﬁstula 0 1 0 1
Gastroparesis 3 4 1 8
Others 0 1 0 1
Death 0 0 0 0
Total/no. of incidents 52 91 15n 158
No. of patients 50 (4.9%) 87 (4.8%) 14 (2.6%) 151 (4.5%)
n po0.05 vs. warfarin, OAC: oral anticoagulant, NOAC: novel oral anticoagulant, AVB: atrioventricular block, PE: pericardial effusion, and TIA: transient ischemic attack.
Fig. 1. Comparison of the incidence of complications. Overall complications were
less frequent in patients treated with NOAC than in patients receiving uninter-
rupted warfarin treatment (po0.05). Incidence of pericardial effusion (PE) was also
lower in patients treated with NOAC than in patients taking warfarin.
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clinical features among the patient groups into consideration, it
cannot be concluded that less frequent complications suggest an
advantage of NOACs over warfarin as a periprocedural antic-
oagulant therapy. Instead, it seems rational to consider that NOACs
are safe substitutes for warfarin.
4.4. Limitations
The present data were retrospectively collected from a large
number of centers. We therefore assumed that the results could
offer a broad perspective of anticoagulant management immedi-
ately before and during AF ablation. On the other hand, because
thrombotic and bleeding events involve multiple factors, such as
the combined use of antiplatelet and heparin therapies, it is not
easy to compare the merits and demerits of different anticoagulant
strategies in a non-randomized retrospective study. The preva-
lence of asymptomatic cerebral infarction might have been under-
estimated by the fact that only a limited proportion of patients
were examined by MRI. Moreover, the diagnosis of complications
was entrusted to each physician. Special care must be taken to
interpret the present results, which might have been biased by the
limitations inherent in observational studies.
In addition, detailed data of when an anticoagulant was given
and for how long it remained in each patient were not included in
the analysis. The potential of the present study to compare the
usefulness of each anticoagulant is inevitably limited.
5. Conclusions
NOACs have come to be used as a feasible periprocedural
anticoagulant for AF ablation. Our results suggest that NOACs are
safe substitutes for warfarin without an excessive increase in
either thromboembolic or bleeding complications.
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